Prostate cancer There is good evidence that<unk>  is an effective treatment for increasing overall survival among people with high-risk non-metastatic castration-resistant prostate cancer, particularly those with a PSA doubling time ≤ 6 months. Other uses<unk>  can be used as an antiandrogen in feminizing hormone therapy for transgender women. Available forms<unk>  is provided in the form of a 40 mg Capsule. It is taken orally at a dosage of 160 mg once per day (four capsules).
Enzalutamide
Bicalutamide
Flutamide
Apalutamide
Nilutamide
Topilutamide
Darolutamide
Tamoxifen